Meta Healthcare today confirmed that the U.S. Food and Drug Administration has granted orphan-drug designation to MH-101, a specialised medicine being advanced for the adjunctive management of hyperammonaemia in patients with urea cycle disorders.
Urea cycle disorders are a group of rare and inherited metabolic conditions in which a deficiency in one or more urea cycle enzymes can lead to elevated levels of ammonia in the blood. Adjunctive management options that complement existing standards of care remain an area of unmet need.
What orphan designation supports
FDA orphan-drug designation is granted to medicines intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the United States. The designation supports continued development of MH-101 and confirms its status as a programme serving a clearly defined rare-disease population.
- Tax credits for qualified clinical trial activity
- Eligibility for orphan-drug grant funding
- Seven years of US market exclusivity if approved
Programme status
MH-101 remains in clinical evaluation. UK and EU territorial rights are retained by Meta Healthcare; US development is funded through the current orphan-pathway programme.
MH-101 is under clinical evaluation and is not approved for marketing in any territory. Statements about regulatory milestones describe orphan-designation status only and do not constitute claims of efficacy or regulatory approval.